56 related articles for article (PubMed ID: 2207197)
1. [The effect of cell migration on the stability of immunogenic multicentric tumors].
Alekseeva EI; Kuznetsov VA
Biofizika; 1990; 35(3):509-12. PubMed ID: 2207197
[TBL] [Abstract][Full Text] [Related]
2. [Computer analysis of the dynamics of two tumor foci with respect to circulating immune cells].
Kuznetsov VA; Alekseeva EI
Biofizika; 1991; 36(1):109-13. PubMed ID: 1854819
[TBL] [Abstract][Full Text] [Related]
3. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
5. Resistance of primary CD8+ cytotoxic T lymphocytes to lysis by cytotoxic granules from cloned T cell lines.
Nagler-Anderson C; Verret CR; Firmenich AA; Berne M; Eisen HN
J Immunol; 1988 Nov; 141(10):3299-305. PubMed ID: 2972770
[TBL] [Abstract][Full Text] [Related]
6. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
7. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor.
Boissonnas A; Fetler L; Zeelenberg IS; Hugues S; Amigorena S
J Exp Med; 2007 Feb; 204(2):345-56. PubMed ID: 17261634
[TBL] [Abstract][Full Text] [Related]
8. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
Marsili MA; Walker MC; Phillips-Quagliata JM
Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
[TBL] [Abstract][Full Text] [Related]
9. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors.
Liu B; Podack ER; Allison JP; Malek TR
J Immunol; 1996 Feb; 156(3):1117-25. PubMed ID: 8557987
[TBL] [Abstract][Full Text] [Related]
10. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
11. T cell-accessory cell interactions that initiate allospecific cytotoxic T lymphocyte responses: existence of both Ia-restricted and Ia-unrestricted cellular interaction pathways.
Singer A; Kruisbeek AM; Andrysiak PM
J Immunol; 1984 May; 132(5):2199-209. PubMed ID: 6201534
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor.
McAdam AJ; Pulaski BA; Storozynsky E; Yeh KY; Sickel JZ; Frelinger JG; Lord EM
Cell Immunol; 1995 Oct; 165(2):183-92. PubMed ID: 7553882
[TBL] [Abstract][Full Text] [Related]
13. Resistance to polyoma virus-induced tumors correlates with CTL recognition of an immunodominant H-2Dk-restricted epitope in the middle T protein.
Lukacher AE; Wilson CS
J Immunol; 1998 Feb; 160(4):1724-34. PubMed ID: 9469430
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring cytotoxic T lymphocyte precursors with specificity for an Ig idiotype.
Dohi Y; Yamada K; Ohno N; Aoki M; Takagaki Y; Nisonoff A; Shinka S
J Immunol; 1988 Dec; 141(11):3804-9. PubMed ID: 2460550
[TBL] [Abstract][Full Text] [Related]
15. A cellular automata model of tumor-immune system interactions.
Mallet DG; De Pillis LG
J Theor Biol; 2006 Apr; 239(3):334-50. PubMed ID: 16169016
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
Mizutani Y; Okada Y; Terachi T; Yoshida O
J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
[TBL] [Abstract][Full Text] [Related]
17. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
18. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
19. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity.
Gordon LB; Nolan SC; Cserr HF; Knopf PM; Harling-Berg CJ
J Immunol; 1997 Sep; 159(5):2399-408. PubMed ID: 9278331
[TBL] [Abstract][Full Text] [Related]
20. Effect of morphine on cell-mediated immune responses of human lymphocytes against allogeneic malignant cells.
Fuggetta MP; Di Francesco P; Falchetti R; Cottarelli A; Rossi L; Tricarico M; Lanzilli G
J Exp Clin Cancer Res; 2005 Jun; 24(2):255-63. PubMed ID: 16110759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
